(24) in 2015, other authors have reported significant reductions in tumor volume and clinical improvement after administration of a single-agent BRAF inhibitor (17, 22, 25, 26), or combined BRAF/MEK inhibitor therapy (19, 23, 24, 26–29), in PCPs harboring the BRAF V600E mutation. Here, BRAF is linked to neoplasm.